Vukomanovic, Ivana (39062340600)Ivana (39062340600)VukomanovicColovic, Vidosav (13613347200)Vidosav (13613347200)ColovicSoldatovic, Ivan (35389846900)Ivan (35389846900)SoldatovicHadzi-Djokic, Jovan (6603561960)Jovan (6603561960)Hadzi-Djokic2025-07-022025-07-022012https://doi.org/10.1007/s12032-011-9999-4https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872827416&doi=10.1007%2fs12032-011-9999-4&partnerID=40&md5=a84deffb1674f450c4a6955b795d51e1https://remedy.med.bg.ac.rs/handle/123456789/13936The management of high-grade (HG) nonmuscle-invasive bladder cancer (NMIBC) continues to be a serious clinical problem. The role of many factors related to efficacy of Bacillus Calmette-Guérin (BCG), which is the most useful intravesical agent for these tumors, is still unknown. This study investigated the prognostic value of tumor location in high-grade non-muscle-invasive bladder cancer. Seventy-four patients with HG non-muscle-invasive bladder cancer, without carcinoma in situ (CIS), were treated by transurethral resection of bladder tumor (TURBT). Twenty-eight patients received adjuvant BCG therapy after TURBT. The relation between tumor location and the recurrence capacity was estimated using a Cox regression model. Our results suggest that tumor location is an important prognostic factor for BCG-therapy response in patients with high-grade non-muscle-invasive bladder cancer. Tumors in the bladder neck might have a higher risk of recurrence after intravesical immunotherapy. In addition, tumors in the lateral and posterior bladder walls might be at higher risk of recurrence when treated by TURBT alone. © Springer Science+Business Media, LLC 2011.BCGBladder cancerImmunotherapyIntravesical instillation